CONTACT
+91 80 2808 2808
info@biocon.com

Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan

  • Posted by: BIOCON

NOTIFICATION TO STOCK EXCHANGE

Company Statement

Bengaluru, India, May 07, 2019

Following the successful approval and European launch of Hulio®, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets.

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets.

Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.

– Biocon Spokesperson

Author: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this